IPO GMP comparison: Jio Platforms and Paras Healthcare were the two major IPOs that opened for subscription on October 21, drawing contrasting responses from investors. While Jio Platforms dominated market attention with strong demand, Paras Healthcare witnessed a relatively subdued response.
The ₹30,213-crore IPO of Jio Platforms attracted robust investor interest and was fully subscribed within just 100 minutes of opening on Wednesday, making it the fastest among the country’s mega IPOs to achieve full subscription.
By 5 pm, the issue had been subscribed 3.01 times, with investors placing bids for 59.44 crore shares against the 19.75 crore shares on offer, according to exchange data. The qualified institutional buyers (QIB) category was subscribed nine times. In contrast, the retail investor portion was subscribed 0.68 times, with bids for 5.78 crore shares against 8.50 crore shares reserved. The employee and shareholder categories received subscriptions of 1.30 times and 1.38 times, respectively.
Meanwhile, Paras Healthcare’s ₹1,450-crore IPO received a lukewarm response on the first day of bidding, with the issue subscribed just 0.15 times by the end of the day. Demand from non-institutional investors (NII) remained weak, with their portion subscribed 0.08 times, while the qualified institutional buyers’ category had not yet opened for subscription. Retail investors showed comparatively better interest, subscribing to 0.73 times the shares reserved for them, according to exchange data.
Jio Platforms IPO vs Paras Healthcare IPO GMP today
The grey market premium (GMP) of Jio Platforms’ IPO eased slightly to ₹246 from ₹273, but the issue continues to command a strong premium in the unlisted market. According to Investorgain, the mega IPO’s GMP stood at ₹246.
Meanwhile, Paras Healthcare IPO GMP trends remained weak. The GMP of Paras Healthcare IPO stood at ₹25, as per data available on Investorgain
Jio Platforms IPO vs Paras Healthcare IPO listing share price prediction
According to current GMP trends, Jio Platforms’ IPO is expected to list at around ₹1,365 per share, implying a potential listing gain of 21.98% over the upper issue price of ₹1,119.
On the other hand, the estimated listing price of Paras Healthcare IPO is likely to be ₹718, which is 3.61% higher than the IPO price of ₹693.
Disclaimer: We advise investors to check with certified experts before making any investment decisions.
